George Poste, DVM, Ph.D.
CEO, Health Technology Networks
Dr. Poste was appointed in May 2003 as the Director of The Biodesign Institute at Arizona State University. This is a major new initiative combining research groups in biotechnology, nanotechnology, materials science, advanced computing and neuromorphic engineering. In addition to his academic post he serves as Chief Executive of a consulting company, Health Technology Networks that specializes in the application of genomic technologies and computing in healthcare. He serves as Non-Executive Chairman of Orchid Biosciences in Princeton and on the Board of Directors of Monsanto and Exelixis. From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as R&D Scientist of the Year’ by R&D Magazine. He is a Fellow of the Royal Society, and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He is a member of the Defense Science Board of the US Department of Defense and in this capacity Chairs the Task Force on Bioterrorism. He is also a member of the Threat Reduction Advisory Committee for the Defense Threat Reduction Agency. He also serves as a member of the National Academy Sciences Working Group on Biological Weapons and the Forum on Microbial Threats of the Institute of Medicine Board on Global Health.